Welcome to our dedicated page for Scienture Holdings SEC filings (Ticker: SCNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scienture Holdings, Inc. (NASDAQ: SCNX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy materials and registration-related documents. Scienture files with the U.S. Securities and Exchange Commission as a Delaware corporation under Commission File Number 001-39199, and its filings offer detailed insight into its specialty pharmaceutical business conducted through its wholly owned subsidiary, Scienture, LLC.
Among the most informative documents for SCNX are current reports on Form 8-K, which describe material events such as financing arrangements, amendments to debt agreements, conversion of secured convertible debentures into common stock, and the issuance of senior secured promissory notes. These filings outline key terms such as principal amounts, original issue discounts, interest rates, security agreements granting liens on company and subsidiary assets, and guaranty obligations. Other 8-Ks address corporate actions including amendments to bylaws, notices from Nasdaq regarding minimum bid price compliance, and results of stockholder votes at the annual meeting.
Scienture’s definitive proxy statement on Schedule 14A is another core filing, setting out proposals submitted to stockholders, including director elections, potential increases in authorized share capital, amendments to the company’s equity incentive plan, authorization for a potential future offering of common stock under Nasdaq Listing Rule 5635(d), and possible reverse stock split authority. The proxy statement also explains governance structures, committee charters and procedures for the annual meeting.
Through Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex topics such as capital structure changes, equity distribution agreements on Form S-3, or listing compliance matters. Users can review historical and recent filings, monitor how Scienture manages its financing and governance, and reference official disclosures related to its specialty products, including Arbli™ and REZENOPY™. This page is a resource for investors seeking structured, regulator-reviewed information on SCNX beyond press releases and market commentary.
Scienture Holdings, Inc. preliminary proxy statement presents several governance and capital-structure proposals for stockholder vote. Key items include a proposal to increase authorized Common Stock from 100,000,000 to 2,000,000,000 shares and Preferred Stock from 10,000,000 to 200,000,000, and a proposed amendment to increase shares available under the 2019 Equity Incentive Plan from 5,000,000 to 25,000,000. The proxy also seeks approval for a potential future offering that could issue more than 20% of currently outstanding common shares at a price below Nasdaq's defined "minimum price."
The document lists director nominees with ages and term expirations, describes a potential Reverse Stock Split with cash in lieu of fractional shares, and details insider trading and anti-hedging policies restricting trades to approved windows or 10b5-1 plans and prohibiting short sales. Vesting and forfeiture terms for restricted stock and administrator discretion to accelerate vesting are explained. Several annexes and committee rules are referenced but not fully reproduced in the excerpt.
Scienture Holdings, Inc. amended its bylaws to lower the shareholder meeting quorum requirement from a majority of voting power to one-third of the voting power. This means future stockholder meetings can proceed and conduct business with fewer shares represented in person, remotely, or by proxy, unless a higher threshold is required by law, the certificate of incorporation, or other bylaw provisions. The rules allowing the chairperson or a majority of voting power present to adjourn meetings until a quorum is reached remain in place.
Scienture Holdings, Inc. entered into a new letter agreement with Arena Finance Markets, LP and Arena Special Opportunities III LP to change key terms of its existing secured convertible debentures. The parties agreed to amend the debentures so that any remaining amounts owed will convert into shares of Scienture common stock at a revised conversion price of $2.4861 per share, resulting in a full conversion of the debt into equity.
Once this full conversion occurs, the debentures and related transaction documents will be terminated, all obligations under those documents will be deemed fully satisfied, and all related security interests and liens held by the Arena investors will be automatically released. After that point, the Arena investors will have no further obligation to extend credit or provide other financial accommodations to Scienture under these arrangements.
Scienture Holdings, Inc. filed a Form 8‑K disclosing an Equity Distribution Agreement dated September 19, 2025 with Maxim Group LLC (Exhibit 1.1). The filing also includes a legal opinion from Dykema Gossett PLLC (Exhibit 5.1) and the firm’s consent (Exhibit 23.1). The submission includes the cover page interactive data file. The report is signed by Dr. Narasimhan Mani, Co‑Chief Executive Officer, dated September 23, 2025. The document lists the material exhibits and provides no financial tables, earnings data, or additional transaction terms in the disclosed text.
Scienture Holdings, Inc. filed a Form 8‑K disclosing an Equity Distribution Agreement dated September 19, 2025 with Maxim Group LLC (Exhibit 1.1). The filing also includes a legal opinion from Dykema Gossett PLLC (Exhibit 5.1) and the firm’s consent (Exhibit 23.1). The submission includes the cover page interactive data file. The report is signed by Dr. Narasimhan Mani, Co‑Chief Executive Officer, dated September 23, 2025. The document lists the material exhibits and provides no financial tables, earnings data, or additional transaction terms in the disclosed text.
Scienture Holdings, Inc. is offering securities under a prospectus supplement that discloses the company currently relies on third-party commercial manufacturing organizations (CMOs) for all production of raw materials, finished dosage forms and packaging and does not own or plan to develop its own manufacturing facilities in the foreseeable future. The prospectus shows common share counts in several states: 126,683,845, 132,309,933, and 141,123,934. It reports stockholder's equity items including negative balances shown as ($48,823,543) and ($49,195,531) and asset or similar aggregates of $77,860,464, $83,114,613, and $91,928,717. Historical net tangible book value per share as of June 30, 2025 is shown as $(1.27). The offering contemplates equity issuance from the conversion of secured convertible promissory notes (Debentures) issued November 25, 2024, conversion of Series B Preferred Stock, and the potential exercise of 2,273,930 options at a weighted average price of $1.22 and 238,594 warrants at a weighted average price of $19.02. The prospectus incorporates the company's Annual Report for year ended December 31, 2024 and Quarterly Reports for March 31 and June 30, 2025, and lists multiple Current Reports filed in 2025.
Scienture Holdings, Inc. is offering securities under a prospectus supplement that discloses the company currently relies on third-party commercial manufacturing organizations (CMOs) for all production of raw materials, finished dosage forms and packaging and does not own or plan to develop its own manufacturing facilities in the foreseeable future. The prospectus shows common share counts in several states: 126,683,845, 132,309,933, and 141,123,934. It reports stockholder's equity items including negative balances shown as ($48,823,543) and ($49,195,531) and asset or similar aggregates of $77,860,464, $83,114,613, and $91,928,717. Historical net tangible book value per share as of June 30, 2025 is shown as $(1.27). The offering contemplates equity issuance from the conversion of secured convertible promissory notes (Debentures) issued November 25, 2024, conversion of Series B Preferred Stock, and the potential exercise of 2,273,930 options at a weighted average price of $1.22 and 238,594 warrants at a weighted average price of $19.02. The prospectus incorporates the company's Annual Report for year ended December 31, 2024 and Quarterly Reports for March 31 and June 30, 2025, and lists multiple Current Reports filed in 2025.
Scoggin-affiliated investors report a small passive stake in Scienture Holdings Inc. The filing discloses that Scoggin International Fund Ltd., Scoggin Management LP, Scoggin GP LLC and individuals Curtis Schenker and Craig Effron each beneficially own 150,000 shares of Scienture common stock, representing 0.01% of the 16,131,180 shares outstanding cited in the filing. The reporting persons state the holdings were not acquired to influence control of the issuer and identify the relationships among the entities: Scoggin GP LLC is the general partner of Scoggin Management LP, which manages Scoggin International Fund Ltd., and Messrs. Schenker and Effron are co-managing members. Exhibits include a joint filing agreement and an Item 8 statement.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 1,075,000 shares of Scienture Holdings, Inc. common stock, representing 5.55% of the outstanding class based on 19,356,180 shares cited in the issuer's prospectus supplement. The filing states the fund has sole voting and sole dispositive power over these shares and includes a standard disclaimer noting two directors of the fund, David Feldman and Joel Arber, may be deemed to have an interest but disclaim beneficial ownership except to the extent of pecuniary interest.
Scienture Holdings, Inc. entered into a registered direct stock offering with institutional investors, selling 3,225,000 common shares at $1.20 per share for gross proceeds of approximately $3.87 million. The sale was made under an effective shelf registration statement on Form S-3 and closed on August 15, 2025. Maxim Group LLC acted as exclusive placement agent and will receive a cash fee equal to 7.0% of the gross proceeds plus up to $50,000 of expense reimbursement. The company agreed not to issue additional equity or file most new registration statements for 15 days after closing, while officers and directors are subject to 90-day lock-ups. Separately, between July 18 and August 11, 2025, Scienture raised about $1.76 million in a private sale of 1,110,060 shares, with proceeds used for working capital, capital spending, product development, and other corporate purposes.
Prospectus supplement summary: The document presents terms of a securities offering and related company disclosures. The placement agent fee is stated as $0.08 per share totaling $270,900, and the proceeds before expenses are shown as $1.12 per share totaling $3,599,100. The filing lists common shares outstanding at various points: 126,683,845, 127,894,248, and 130,828,731. A historical net tangible book value per share is disclosed as $(1.27). The company notes anticipated capitalization changes from the conversion of secured convertible promissory notes, conversion of Series B preferred stock, and potential exercise of 2,270,672 options (weighted average exercise price $1.22) and 238,594 warrants (weighted average exercise price $19.02). The filing also states that Scienture, LLC relies on third‑party CMOs for all manufacturing and does not own manufacturing facilities.
Scienture Holdings, Inc. (f/k/a TRxADE Health) reported a weak operating quarter with minimal revenue and mounting losses while consolidating a major acquisition. Total assets were $104.3 million, driven primarily by $76.4 million of acquired product technology intangibles and $21.37 million of goodwill from the July 25, 2024 Scienture acquisition. One product, SCN-102, received regulatory approval in March 2025 and commercialization is projected to begin in 2025.
Operating results show revenues of $10,258 for the six months ended June 30, 2025 and a net loss from continuing operations of $9.78 million for the same period (quarter loss $6.72 million). Cash on hand was $15,391 at June 30, 2025 and the company discloses substantial doubt about its ability to continue as a going concern. The company completed divestitures of legacy subsidiaries for a $5.0 million promissory note and maintains convertible debentures and a derivative liability related to a $3.33 million Arena financing.